ACT Brief: Moving Beyond AI Pilots, FDA Advances Bayesian Trials, and Sites Strained by Trial Design
In today’s ACT Brief, we examine what will separate sponsors that scale AI beyond pilots in 2026, break down the FDA’s new ...
FDA proposes framework clinical trial designs to guide Bayesian methods, improving efficiency in drug development for rare and pediatric conditions.
The FDA’s new draft guidance on Bayesian methodology signals a shift toward more flexible, data-driven clinical trial designs, enabling sponsors to use prior data and adaptive approaches to improve ...
US FDA issues guidance on modernizing statistical methods for clinical trials: Maryland Wednesday, January 14, 2026, 09:00 Hrs [IST] The US Food and Drug Administration today publ ...
Bayesian prediction and modeling have emerged as transformative tools in the design and management of clinical trials. By integrating prior knowledge with accumulating trial data, Bayesian methods ...
Bayesian methods have emerged as a pivotal framework in the design and analysis of clinical trials, offering a systematic approach for updating evidence as new data become available. By utilising ...
Phase 1a/1b study in 97 patients demonstrates mitochondrial metabolic reprogramming induced by BPM31510-IV and supports advancement in multiple aggressive solid tumor indications. BPM31510-IV has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback